ライフサイエンスコーパス: Beckman

1 th present) using multimodal imaging and the Beckman and Classification of Atrophy Meetings criteria.

2 s Disease', was held at the Arnold and Mabel Beckman Center in Irvine, California.

3 te AMD, and late AMD graded according to the Beckman clinical classification system.

4 w-up 22 [13-41] months; 31 [23%] deaths) and Beckman cohort (n=98; median follow-up 19 [12-28] months

5 or 18-month mortality of the combined Abbott/Beckman cohorts (n=234) was 81 ng/L, rounded to 80 ng/L

6 he results were correlated to the commercial Beckman Colter, Hybritech immunoassay(R) for determinati

7 Abbott Architect Stat hs-cTnI assay and the Beckman Coulter Access hs-cTnI assay (testing cohorts) a

8 rogen ChargeSwitch-Pro PCR Purification, and Beckman Coulter AMPure XP.

9 Assay for use on the new and fully automated Beckman Coulter DxN Veris Molecular Diagnostics System (

10 -1 assay for use on the new, fully automated Beckman Coulter DxN Veris molecular diagnostics system w

11 BD Phoenix, bioMerieux Vitek 2, and Beckman Coulter MicroScan commercial automated susceptib

12 es fixed in osmium tetroxide and analyzed by Beckman Coulter Multisizer.

13 and 0- and 2-hour high-sensitivity troponin (Beckman Coulter) measures were used to stratify patients

14 nd 2-hour high-sensitivity cardiac troponin (Beckman Coulter) measures.

15 In this method, the Vi-CELL (Beckman Coulter) was used to measure cell diameter chang

16 ed to microparticle size analysis (RapidVue, Beckman Coulter).

17 copy every 10 years, annual Hemoccult SENSA (Beckman Coulter, Fullerton, California) testing or fecal

18 l blood cards (Hemoccult and HemoccultSensa, Beckman Coulter, Fullerton, California) were tested on 3

19 ted the Phoenix (BD, Sparks, MD), MicroScan (Beckman Coulter, Sacramento, CA), and Vitek2 (bioMerieux

20 ood, MO, USA) and MicroScan NM56 AST panels (Beckman Coulter, Sacramento, CA, USA).

21 nalytical ultracentrifuge, the Optima AUC by Beckman Coulter.

22 gh, MA), Hemoccult, and HemoccultSensa (both Beckman-Coulter, Fullerton, CA).

23 assays (hs-cTnT, Roche Diagnostics; hs-cTnI, Beckman-Coulter; hs-cTnI Siemens) in a blinded fashion a

24 In 2020, the Arnold and Mabel Beckman Foundation introduced blinding to the first stag

25 or fundus photographs in accordance with the Beckman Initiative for Macular Research classification s

26 AMD, defined according to the Beckman Initiative for Macular Research, was assessed by

27 e Boltzmann transport equation and using the Beckman-Kirchhoff surface scattering theory with shadowi

28 t the University of California-Irvine Health Beckman Laser Institute & Medical Clinic, Irvine, betwee

29 o stated that cell counting was done using a Beckman Multisizer 3 Coulter Counter, but a CASY Model T

30 c ketones that are converted to imines via a Beckman rearrangement reaction.

31 g factors, were centrifuged at 3000 rpm in a Beckman Sanderson Chamber.

32 alibrate quality values that come along with Beckman sequencers.

33 the process used to review applications for Beckman Young Investigator (BYI) awards: applicants were